13F Holdings
中文EN

KMTS KESTRA MEDICAL TECHNOLOGIES, LTD.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1877184 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY60.7%
TTM net income YoY-25.1%
TTM EPS YoY40.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin53.9%
Operating margin-134.5%
Net margin-140.4%
FCF margin-115.0%
EBITDA margin-125.7%

Returns

ROE-73.7%
ROA-48.8%
ROIC (approx.)-90.4%
Asset turnover0.35x

Leverage & solvency

Liabilities / assets36.0%
Debt / equity0.33x
Current ratio4.69x
Interest coverage-18.98x

Cash quality & payout

Operating cash flow / net income0.59x
Accruals ratio-20.3%
Payout ratio—
Capex / revenue32.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-04-30FY20252025-04-30FY20242024-04-30
Income statement
Revenue$95.13M$59.81M$27.81M
Cost of revenue$46.26M$35.60M$27.45M
Gross profit$48.86M$24.21M$362,000
R&D expense$19.48M$15.65M$15.49M
SG&A expense$164.12M$114.94M$69.94M
Operating income-$134.74M-$106.38M-$85.06M
Interest expense$7.55M$7.73M$6.23M
Pretax income-$131.32M-$113.68M-$94.10M
Income tax$294,000$135,000$24,000
Net income-$131.61M-$113.81M-$94.12M
EBITDA-$126.03M-$98.41M-$73.50M
EPS (basic)-2.43-5.13-5.07
EPS (diluted)-2.43-5.13-5.07
Weighted avg. shares (diluted)54.18M24.58M19.89M
Balance sheet
Cash & equivalents$99.71M$237.93M$8.58M
Short-term investments$96.72M——
Receivables$14.54M$8.08M$2.00M
Current assets$222.36M$255.33M$14.91M
PP&E, net$59.09M$34.83M$26.11M
Total assets$358.46M$295.74M$45.95M
Current liabilities$50.37M$37.98M$32.97M
Long-term debt$42.65M$41.10M$42.54M
Total debt$42.65M$41.10M$42.54M
Total liabilities$98.81M$90.34M$78.22M
Shareholders' equity$259.66M$205.41M-$209.38M
Net debt-$57.06M-$196.83M$33.95M
Shares outstanding58.38M51.35M105,808
Cash flow statement
Operating cash flow-$81.70M-$77.61M-$72.23M
Capital expenditure$34.89M$22.94M$12.23M
Free cash flow-$116.59M-$100.54M-$84.46M
Investing cash flow-$203.28M-$23.31M-$12.23M
Financing cash flow$147.09M$330.26M$77.72M
Depreciation & amortization$8.71M$7.97M$11.56M
Stock-based compensation$33.64M$24.27M$1.49M

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.